Outlook Therapeutics, Inc. — Director's Dealing 2017

Oct 30, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncobiologics, Inc. (ONS)
CIK: 0001649989
Period of Report: 2017-10-26

Reporting Person: Brady Todd C (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-26	Stock Option (Right to Buy)	$1.32	A	15000	Acquired	2027-10-26	Common Stock (15000)	Direct

Footnotes

F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date.